1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,260 | 1,320 | 12:57 | |
| 1,260 | 1,310 | 10:17 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am | 483 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 22.10. | NanoViricides President Dr. Diwan to Present at the PODD Conference | 278 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 15.10. | NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology | 446 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 14.10. | NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy | 1 | Insider Monkey | ||
| 08.10. | InvestorNewsBreaks - NanoViricides Inc. (NYSE American: NNVC) to Discuss Its 'Trojan Horse' Platform Technology at Upcoming Global AMR Summit | 1 | iNVEZZ.com | ||
| 08.10. | NanoViricides to Present at the Global AMR Summit 2024 Tomorrow | 410 | ACCESSWIRE | Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides... ► Artikel lesen | |
| 30.09. | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID | 430 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30... ► Artikel lesen | |
| 27.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 26.09. | NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs | 541 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that... ► Artikel lesen | |
| 26.08. | MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX | 539 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it... ► Artikel lesen | |
| 19.08. | NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections | 813 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 09.08. | NanoViricides extends executive contracts, grants stock | 1 | Investing.com | ||
| 09.08. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics | 553 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 01.08. | "NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides | 619 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate... ► Artikel lesen | |
| 24.07. | COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides | 665 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today reminds the strong... ► Artikel lesen | |
| 11.07. | A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides | 598 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development... ► Artikel lesen | |
| 24.06. | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides | 590 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum... ► Artikel lesen | |
| 20.06. | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model | 740 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and global leader in broad-spectrum antiviral nanomedicines, reports that... ► Artikel lesen | |
| 11.06. | NanoViricides, Inc.: Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect | 554 | ACCESSWIRE | A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides... ► Artikel lesen |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 47,450 | +1,06 % | Formycon AG: Segmentwechsel | Formycon AG,
München
ISIN: DE000A1EWVY8
bisheriges Segment: Freiverkehr - Scale
künftiges Segment: Regulierter Markt - Prime Standard
Änderung ab 12. November 2024
Frankfurt am Main, den... ► Artikel lesen | |
| GAUZY | 8,260 | 0,00 % | Gauzy Ltd. GAAP EPS of -$0.29 beats by $0.07, revenue of $23.3M misses by $2.37M | ||
| VEECO INSTRUMENTS | 26,000 | 0,00 % | Veeco stock touches 52-week low at $27.33 amid market shifts | ||
| ONTO INNOVATION | 156,00 | -0,64 % | Onto Innovation Reports 2024 Third Quarter Results | WILMINGTON, Mass.--(BUSINESS WIRE)--Onto Innovation Inc. (NYSE: ONTO) ("Onto Innovation," "Onto," or the "Company") today announced financial results for the third fiscal quarter of 2024.
Third... ► Artikel lesen | |
| DOTZ NANO | 0,056 | +8,82 % | DOTZ NANO LIMITED: Change of Director's Interest Notice - M Board | ||
| KOPIN | 0,810 | -2,47 % | Kopin Corp Q3 Loss Increases, But Beats Estimates | WASHINGTON (dpa-AFX) - Kopin Corp (KOPN) reported Loss for its third quarter that increased from last year but beat the Street estimates.The company's earnings came in at -$3.46 million, or... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,109 | -1,36 % | FendX Technologies Inc.: FendX Announces Granting of United States Patent to Protect REPELWRAP Film | Oakville, Ontario--(Newsfile Corp. - November 14, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX") a nanotechnology company developing surface protection... ► Artikel lesen | |
| REGION GROUP | 1,287 | -2,71 % | REGION GROUP: Initial Director's Interest Notice | ||
| ACACIA RESEARCH | 4,000 | +1,01 % | Acacia Research Reports Third Quarter 2024 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company"), which acquires and operates businesses across the industrial, energy and technology sectors, today... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,430 | 0,00 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LEHNER INVESTMENTS | 0,015 | 0,00 % | EQS-DD: LEHNER INVESTMENTS AG: RIMIVY LTD, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.07.2024 / 16:36... ► Artikel lesen | |
| NANOFOCUS | 1,125 | 0,00 % | NanoFocus passt Prognose für 2024 an | Die NanoFocus AG hat heute beschlossen, die Prognose für das laufende Jahr anzupassen. Aufgrund von gegenwärtig absehbar deutlich niedrigeren Umsätzen in den Bereichen Semiconductor Asia und Standard/Labor... ► Artikel lesen | |
| RIBER | 2,500 | 0,00 % | RIBER: Solid Business Growth at End-September 2024 | SOLID BUSINESS GROWTH AT END-SEPTEMBER 2024 Revenues up +14% to €18.5mOrder book strengthened to €38.3m (+14%) Bezons, October 30, 2024 - 8:00am - RIBER, the global leader for molecular beam epitaxy... ► Artikel lesen | |
| ZENTEK | 0,885 | +13,46 % | Zentek and Triera Biosciences Ltd. Receive $1.1 Million Government of Canada Contract to Test Multivalent Aptamer Technology | GUELPH, ON / ACCESSWIRE / November 6, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has received... ► Artikel lesen | |
| GOMSPACE | 0,339 | 0,00 % | GOMSPACE A/S: ESA and GomSpace sign 8.4 MSEK contract change notice for the GOMX-5 project |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 1,290 Euro und damit +0,78 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.
